“EVERLAST-A: A Phase 2a Study Design of ORKA-001, a Novel Half-Life Extended IL-23p19 Monoclonal Antibody for Plaque Psoriasis”. SKIN The Journal of Cutaneous Medicine, vol. 9, no. 6, Nov. 2025, p. s633, https://doi.org/10.25251/jg65bt44.